What is Mycobacterium avium complex (MAC)?

Mycobacterium avium Complex (MAC): Definition and Clinical Overview

Mycobacterium avium complex (MAC) is a group of ubiquitous environmental nontuberculous mycobacteria, primarily comprising M. avium and M. intracellulare, that causes disseminated disease in severely immunocompromised patients (especially those with HIV and CD4+ counts <100 cells/µL) and pulmonary disease in immunocompetent individuals with underlying lung conditions. 1, 2

Microbiology and Environmental Sources

MAC bacteria are acid-fast organisms with distinctive cell wall structures that make them resistant to many disinfectants 3. These organisms are found throughout the environment in:

• Fresh water, sea water, and soil 1
• Dairy products 1
• Various animals including chickens, pigs, dogs, cats, and insects 1
• Food sources 3

The gastrointestinal tract is considered the most common portal of entry and site of colonization, though the respiratory tract also serves as a route of infection 1.

Clinical Manifestations

Disseminated MAC Disease (Primarily in HIV/AIDS)

Disseminated MAC characteristically occurs in patients with advanced HIV disease and CD4+ T-lymphocyte counts below 100 cells/µL 1. The disease manifests with:

• Fever, night sweats, and weight loss 1
• Anemia and elevated alkaline phosphatase 1
• Diarrhea and abdominal pain 1
• Intra-abdominal lymphadenopathy and hepatosplenomegaly 1

Diagnosis is most readily established by one positive blood culture 1. Blood cultures should be performed in symptomatic patients but are not routinely recommended for asymptomatic individuals, even those with CD4+ counts <100 cells/µL 1.

MAC Pulmonary Disease (MAC-PD)

MAC is the most common nontuberculous mycobacterial respiratory pathogen worldwide, with increasing global prevalence 4, 5, 6. In Korea, prevalence increased from 11.4 to 56.7 per 100,000 individuals between 2010 and 2021, surpassing tuberculosis incidence 4.

Two distinct radiographic patterns exist 1, 6:

• Fibrocavitary disease: Similar to pulmonary tuberculosis, always progressive, requiring immediate treatment 1, 6
• Nodular bronchiectatic (NB) disease: Most common form in the United States, more indolent, may not require immediate antimycobacterial therapy 1, 6

Common clinical features include chronic cough (approximately 78% of patients), exacerbations (50-54%), and hospitalizations (17-18%) 7.

Treatment Principles

For Disseminated MAC (HIV/AIDS Patients)

Treatment regimens must include at least two agents, with every regimen containing either azithromycin or clarithromycin; ethambutol is preferred as the second drug 1. Additional agents may include clofazimine, rifabutin, rifampin, ciprofloxacin, and amikacin 1. Notably, isoniazid and pyrazinamide are not effective for MAC therapy 1.

Therapy should continue for the patient's lifetime if clinical and microbiologic improvement is observed 1. Most responding patients show substantial clinical improvement within 4-6 weeks, with blood culture sterilization requiring 4-12 weeks 1.

For MAC Pulmonary Disease

The cornerstone of MAC-PD therapy is a three-drug regimen consisting of a macrolide (clarithromycin or azithromycin), rifampin, and ethambutol, administered for a minimum of 12 months following culture conversion 1, 4, 5.

Macrolides should never be used as monotherapy to prevent emergence of macrolide resistance 1. Ethambutol plays a crucial role in preventing macrolide resistance development 4.

For nodular/bronchiectatic disease or patients unable to tolerate daily therapy, intermittent three-times-weekly dosing is recommended: clarithromycin 1,000 mg or azithromycin 500-600 mg, ethambutol 25 mg/kg, and rifampin 600 mg 1.

Treatment Outcomes and Challenges

Treatment success rates are approximately 60% in treatment-naïve patients without macrolide resistance when adhering to guideline-based therapy 4, 5. However, over 30% of patients experience recurrence, often due to reinfection rather than relapse 4.

Antimicrobial susceptibility testing for clarithromycin and amikacin is essential, as resistance significantly worsens prognosis 4. Macrolide resistance leads to particularly poor outcomes and high mortality 6.

For refractory MAC-PD (defined as remaining culture positive ≥6 months during treatment or requiring advanced therapies), adjunctive therapy with inhaled amikacin is advised 7. Emerging strategies include clofazimine-bedaquiline combinations for macrolide-resistant cases, showing significant reductions in bacterial loads in murine models 8.

Prophylaxis (HIV/AIDS Patients)

Patients with HIV infection and CD4+ counts <100 cells/µL should receive rifabutin 300 mg daily for prophylaxis 1. Before initiating prophylaxis, patients must be assessed to exclude active MAC, M. tuberculosis, or other mycobacterial disease through chest radiograph and tuberculin skin testing 1.

Important Clinical Pitfalls

• Co-infections or co-colonizations with different MAC strains or species occur in approximately 33% of patients with serial isolates 2
• MAC bacteria demonstrate clustering patterns suggesting potential transmission routes, though these remain incompletely defined 2
• The disease burden is substantial even before patients meet criteria for refractory disease, with exacerbations and hospitalizations common throughout the disease course 7
• Treatment is lengthy and often fails due to microbiological relapse, with increasing evidence of multi-drug resistance development 3